Keros halts hypertension treatment trial on safety issues
By Thomson ReutersJan 15, 2025 | 5:41 AM
(Reuters) – Keros Therapeutics said on Wednesday it would voluntarily halt testing of its experimental hypertension treatment due to safety concerns during a mid-stage trial.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.